China gave the greenlight to Eli Lilly & Co.’s blockbuster drug tirzepatide for use in treating diabetes, a move that will intensify the drugmaker’s rivalry with Novo Nordisk A/S over weight ...
Both Eli Lilly and Novo Nordisk are racing to increase production in response to the skyrocketing demand for weight-loss drugs.
Dave Ricks is pushing his scientists to find an even more potent anti-obesity treatment. “Lilly’s got a lead, and we plan to ...
Doctors prescribe Lilly's Mounjaro and Zepbound to help patients manage their weight, and the results have been fantastic.
, opens new tab said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk (NOVOb.CO ...
Eli Lilly (LLY) posts detailed mid-stage results highlighting the benefits of its weight loss drug tirzepatide against a ...
The anti-obesity drug market will be worth $130 billion by 2030, Goldman Sachs analysts said in a research note.
China alone, the market is expected to grow to 14.9 billion yuan ($2 billion) by 2030. The approval is potentially paving the way for off-label use of Tirzepatide for weight loss, similar to Wegvoy.
Benzinga - by Vandana Singh, Benzinga Editor. On Tuesday, Eli Lilly And Company (NYSE:LLY) announced that Chinese regulators have approved its diabetes drug tirzepatide. This approval sets the stage ...